[{"id":"17e179ba-af45-4910-b3e7-1e15f44c5d04","acronym":"","url":"https://clinicaltrials.gov/study/NCT05927779","created_at":"2023-07-03T16:10:23.510Z","updated_at":"2024-07-02T16:35:44.245Z","phase":"Phase 1/2","brief_title":"Study of TFX06 in Women With Advanced Breast Cancer.","source_id_and_acronym":"NCT05927779","lead_sponsor":"Shenzhen Yangli Pharmaceutical Technology Co., Ltd","biomarkers":" HER-2 • CDK4","pipe":" | ","alterations":" ER mutation • ESR1 mutation","tags":["HER-2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER mutation • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TFX06"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 04/17/2023","start_date":" 04/17/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2023-06-30"}]